Moneycontrol PRO
HomeNewsBusinessEarningsLupin Q3 results: Net profit jumps four times to Rs 613 crore, revenue up 20%

Lupin Q3 results: Net profit jumps four times to Rs 613 crore, revenue up 20%

The company had reported a profit of Rs 157.6 crore in the same period last year.

February 07, 2024 / 21:30 IST
Lupin's revenue came in at Rs 5,197.4 crore
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Pharma major Lupin Ltd. on February 7 reported a 300 percent year-on-year rise in consolidated net profit at Rs 613 crore for the October-December quarter of the current financial year.

    The company had reported a profit of Rs 157.6 crore in the same period last year.

    Revenue came in at Rs 5,197.4 crore, up  percent from the year-ago quarter numbers of Rs 4,322.2 crore.

    The company delivered its  highest quarterly sales to date and crossed the 5,000 crore mark for the first time, driven by strong growth across

    geographies, according to a statement.

    The company's earnings before interest, taxes, depreciation and amortization (EBITDA) came in at Rs 1,037.9 crore, up 95 percent from Rs 532.7 crore in the year-ago period. The EBITDA margin came in at 20 percent, as against 12.3 percent in the year-ago period.

    Commenting on the results, Nilesh Gupta, Managing Director, Lupin Limited said, "The U.S. continues to do well driven by demand for both in inline products and new launches, and the India business continues to grow ahead of market with strong growth across our key therapies. This positive growth momentum coupled with cost optimization measures and operating leverage has helped us deliver solid performance”.

    North America sales for Q3 FY2024 were Rs 1888.5 crore, up 1.2 percent compared to Rs 1866.6 crore in Q2 FY2024; up 23.7 percent as compared to Rs 1527.1 crore in Q3 FY2023; and accounted for 37 percent of Lupin’s global sales.

    India sales for Q3 FY2024 were Rs 1725.1 crore, up 2 percent as compared to Rs 1691.5 crore in Q2 FY2024; up 13.4 percent as compared to Rs 1521.3 crore in Q3 FY2023; and accounted for 34 percent of Lupin’s global sales.

    Lupin's investment in R&D was Rs 356.7 crore (7 percent of sales) for Q3 FY2024 as compared to Rs 289.6 crore (6.8 percetn of sales) for Q3 FY2023.

    Lupin received approval for 14 ANDAs from the U.S. FDA in the quarter.

    Moneycontrol News
    first published: Feb 7, 2024 08:06 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347